Ultragenyx Pharmaceutical Inc. (RARE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80M 160M 240M Q3 '21: 81.6M Q4 '21: 83.4M Q1 '22: 79.9M Q2 '22: 89.3M Q3 '22: 90.7M Q4 '22: 103.3M Q1 '23: 100.5M Q2 '23: 108.3M Q3 '23: 98.1M Q4 '23: 127.1M Q1 '24: 108.8M Q2 '24: 147M Q3 '24: 139.5M Q4 '24: 164.6M Q1 '25: 139M Q2 '25: 167M Q3 '25: 159.9M Q4 '25: 207.3M Q1 '26: 136M Q2 '26: 214M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 8M 16M 24M Q1 '18: 10.5M Q2 '18: 12.7M Q3 '18: 11.5M Q4 '18: 15.8M Q1 '19: 17.7M Q2 '19: 23.4M Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '21: -89.8M Q4 '21: -102.6M Q1 '22: -136.6M Q2 '22: -141.6M Q3 '22: -225.1M Q4 '22: -145.6M Q1 '23: -154.1M Q2 '23: -148M Q3 '23: -145.1M Q4 '23: -121.8M Q1 '24: -165.3M Q2 '24: -116.4M Q3 '24: -132M Q4 '24: -122.3M Q1 '25: -143M Q2 '25: -108M Q3 '25: -170.9M Q4 '25: -113.3M Q1 '26: -169M Q2 '26: -75M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-270M -180M -90M 0 90M 180M 270M Q3 '21: -73M Q4 '21: -122.5M Q1 '22: -152.3M Q2 '22: -158.2M Q3 '22: -245.1M Q4 '22: -151.8M Q1 '23: -164M Q2 '23: -159.8M Q3 '23: -159.6M Q4 '23: -123.6M Q1 '24: -170.7M Q2 '24: -131.6M Q3 '24: -133.5M Q4 '24: -133.2M Q1 '25: -151M Q2 '25: -115M Q3 '25: -180.4M Q4 '25: -128.6M Q1 '26: -185M Q2 '26: -92M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 300K 600K 900K Q1 '18: 225K Q2 '18: 141K Q3 '18: 273K Q4 '18: 507K Q1 '19: 452K Q2 '19: 766K Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19

Operating Cash Flow Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '21: -59.6M Q4 '21: -54.3M Q1 '22: -117.5M Q2 '22: -77.3M Q3 '22: -95.3M Q4 '22: -90.3M Q1 '23: -156.9M Q2 '23: -116.2M Q3 '23: -117.9M Q4 '23: -84.1M Q1 '24: -190.7M Q2 '24: -77M Q3 '24: -67M Q4 '24: -79.3M Q1 '25: -166M Q2 '25: -109M Q3 '25: -91.2M Q4 '25: -99.8M Q1 '26: -197M Q2 '26: -97M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '21: -80.2M Q4 '21: -70.4M Q1 '22: -149.7M Q2 '22: -108.2M Q3 '22: -121.4M Q4 '22: -117.3M Q1 '23: -181.9M Q2 '23: -130.1M Q3 '23: -121.6M Q4 '23: -85.4M Q1 '24: -193.9M Q2 '24: -79M Q3 '24: -68.6M Q4 '24: -79.5M Q1 '25: -167M Q2 '25: -112M Q3 '25: -92.2M Q4 '25: -100.8M Q1 '26: -198M Q2 '26: -98M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '18: 49.1M Q1 '19: 53.2M Q2 '19: 57.5M Q2 '20: 61.1M Q2 '21: 67.6M Q3 '21: 67.9M Q1 '22: 69.5M Q2 '22: 69.9M Q3 '22: 70.1M Q1 '23: 70.4M Q2 '23: 70.9M Q3 '23: 71.7M Q1 '24: 84.3M Q2 '24: 86.6M Q3 '24: 95.5M Q1 '25: 96.3M Q2 '25: 98.5M Q3 '25: 99.8M Q1 '26: 100.6M Q2 '26: 101.9M Q1 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q3 '21: -5.29 Q4 '21: -6.71 Q1 '22: -6.87 Q2 '22: -7.32 Q3 '22: -9.74 Q4 '22: -10.11 Q1 '23: -10.25 Q2 '23: -10.24 Q3 '23: -8.97 Q4 '23: -8.25 Q1 '24: -7.95 Q2 '24: -7.22 Q3 '24: -6.39 Q4 '24: -6.33 Q1 '25: -5.87 Q2 '25: -5.52 Q3 '25: -5.93 Q4 '25: -5.83 Q1 '26: -6.10 Q2 '26: -5.83 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.